This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Alnylam's (ALNY) Q3 Earnings & Revenues Fall Shy of Estimates
by Zacks Equity Research
Alnylam's (ALNY) earnings and sales miss estimates in the third quarter of 2021. The company reiterates its financial guidance for 2021. Stock down.
Alnylam Pharmaceuticals (ALNY) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Alnylam (ALNY) delivered earnings and revenue surprises of -13.91% and -15.25%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alnylam (ALNY) Files MAA to EMA for Rare Disease Drug Vutrisiran
by Zacks Equity Research
Alnylam (ALNY) submits a marketing authorization application to the EMA for vutrisiran to treat adult patients with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.
Alnylam (ALNY) Up 7.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Alnylam (ALNY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Alnylam's (ALNY) Q2 Earnings Miss Estimates, 2021 Guidance Up
by Zacks Equity Research
Alnylam (ALNY) misses Q2 estimates for earnings but beats the same for sales. The company raises revenue guidance for 2021.
Alnylam Pharmaceuticals (ALNY) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alnylam (ALNY) delivered earnings and revenue surprises of -2.55% and 10.40%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stock Q2 Earnings on Aug 3: LLY, AMGN & More
by Kinjel Shah
Let us take a look at four drug/biotech companies, LLY, AMGN, INCY and ALNY, which are gearing up for their earnings release.
Analysts Estimate Alnylam Pharmaceuticals (ALNY) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alnylam's (ALNY) NDA For Vutrisiran Gets FDA Acceptance
by Zacks Equity Research
The FDA accepts Alnylam's (ALNY) NDA for vutrisiran to treat adult patients with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. A decision is due on Apr 14, 2022.
Apellis' (APLS) Empaveli Succeeds in Treatment-Naive PNH Study
by Zacks Equity Research
Apellis' (APLS) recently approved drug, Empaveli, demonstrates superiority in hemoglobin stabilization and reduction in LDH level in treatment-naive PNH patients.
Apellis (APLS) Gets a Boost With FDA Approval of PNH Drug
by Zacks Equity Research
Approval of Apellis' (APLS) Empaveli for the treatment of paroxysmal nocturnal hemoglobinuria in the United States lends a significant boost to the company's growth prospects.
Ironwood's (IRWD) Q1 Earnings Beat, 2021 Guidance Muted
by Zacks Equity Research
Ironwood (IRWD) witnesses strong demand for Linzess in the first quarter. However, outlook for 2021 misses market expectations. Stock down.
Alnylam's (ALNY) Q1 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Alnylam (ALNY) beat estimates for both earnings and revenues in the first quarter of 2021.
Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alnylam (ALNY) delivered earnings and revenue surprises of 2.29% and 0.36%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Alnylam Pharmaceuticals (ALNY) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ironwood (IRWD) Q4 Earnings Beat on Solid Linzess Sales
by Zacks Equity Research
Ironwood (IRWD) witnesses strong demand for Linzess in the fourth quarter. However, outlook for 2021 misses market expectations.
Alnylam's (ALNY) Q4 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Alnylam (ALNY) reported a wider-than-expected loss but revenues beat estimates in the fourth quarter of 2020.
Alnylam Pharmaceuticals (ALNY) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alnylam (ALNY) delivered earnings and revenue surprises of -8.29% and 14.79%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Vir Biotech, Glaxo to Begin Study on Second COVID-19 Therapy
by Zacks Equity Research
Vir Biotechnology (VIR) and its British partner, Glaxo announces agreement umder which they will evaluate their second coronavirus therapeutic candidate.
Alnylam (ALNY) Posts Positive Top-Line Data From Vutrisiran Study
by Zacks Equity Research
Alnylam (ALNY) reports positive top-line results from the phase III -HELIOS-A study of vutrisiran in development for the treatment of transthyretin-mediated amyloidosis with polyneuropathy.
Novartis (NVS) Gets CRL From the FDA for Cholesterol Drug
by Zacks Equity Research
Novartis (NVS) gets CRL from the FDA for its cholesterol drug, inclisiran, due to unresolved facility inspection-related conditions.
Why Is Alnylam (ALNY) Down 6% Since Last Earnings Report?
by Zacks Equity Research
Alnylam (ALNY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Alnylam (ALNY) Ends Enrollment in Advanced Hyperoxaluria Study
by Zacks Equity Research
Alnylam (ALNY) completes enrollment in its phase III study of Oxlumo for the treatment of advanced primary hyperoxaluria type 1.
Biotech Stock Roundup: REGN's Cocktail Gets EUA, GILD & AMGN Provide Updates & More
by Zacks Equity Research
Pipeline and regulatory updates take centerstage in the biotech sector as Regeneron (REGN) and Gilead Sciences (GILD), among others, provide updates on their pipeline candidates.